Delenex Therapeutics AG is a privately-held biopharmaceutical company developing locally or topically applied antibody therapeutics using its proprietary PENTRA platform. The company focuses on PENTRA Bodies to deliver potent, safe antibody therapeutics for dermatologic diseases and extend benefits of antibodies to more patients. Its clinical lead is the anti-TNFα PENTRABody DLX105, currently in a phase 2a psoriasis study with data expected in mid-2014. Recent proceeds will be used to finish that phase 2a study, advance development of PENTRA Bodies toward clinical development, and exploit the PENTRA antibody and technology platform to generate novel products. Delenex is based in Schlieren and was founded in September 2009 as a spin-off from ESBATech. The company has extended its Series A financing, reflecting continued investor commitment to its dermatology franchise and pipeline. Delenex Therapeutics is a Schlieren (Zurich), Switzerland-based biotech developing therapeutic antibody fragments using its PENTRA® platform. Its core product effort includes DLX105, an anti-TNFalpha single-chain Fv antibody targeting inflammatory diseases. The company plans to bring DLX105 to proof of concept in inflammatory indications, including dermatology, and to evaluate its PENTRA antibodies against additional targets. Financially, Delenex extended its Series A by CHF16.7m ($19.3m), bringing the round total to CHF30.2m ($34.8m). The funding was led by Novo Ventures with participation from SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners. In conjunction with the financing Novo's Thomas Dyrberg will join the board; management includes CEO Eric de La Fortelle, CSO Titus Kretzschmar and CFO Jakob Schlapbach. Delenex develops therapeutic antibody fragments targeting central nervous system, inflammatory, respiratory and dermatologic diseases. The company recently closed a CHF13.5m (≈US$14m, €10m) Series A venture capital financing. It intends to use the funding to advance its antibody fragment programs and initiate additional clinical trials in the near future. Delenex was spun out of ESBATech AG in September 2009 and has rights to further develop, apply and commercially exploit the clinically validated ESBATech antibody technology and products outside ophthalmology. The company is based in Zürich‑Schlieren, Switzerland. Management includes Thomas Hecht MD (Executive Chairman), Titus Kretzschmar PhD (Chief Scientific Officer) and Hamish Cameron MD (Business Development).

Total raised

$41M

Funding rounds

3

Latest round

Series A

Latest activity

Nov 2013